Lanthanum carbonate, like sevelamer-HCl, retards the progression of vascular calcification and atherosclerosis in uremic apolipoprotein E-deficient mice

Nephrology Dialysis Transplantation

Volumn 27, Issue 2, 2012, Pages 505-513

  Nikolov, Igor G ^a,e   Joki, Nobuhiko ^a   Nguyen Khoa, Thao ^b   Guerrera, Ida Chiara ^b   Maizel, Julien ^a   Benchitrit, Joyce ^a   MacHado Dos Reis, Luciene ^c   Edelman, Aleksander ^b   Lacour, Bernard ^b   Jorgetti, Vanda ^c   Drüeke, Tilman B ^a   Massy, Ziad A ^a,d  

^a INSERM   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d AMIENS UNIVERSITY HOSPITAL   (France)

^e SS CYRIL AND METHODIUS UNIVERSITY OF SKOPJE   (Macedonia)

Author keywords

apoE mouse; atherosclerosis; bone histomorphometry; CRF; vascular calcification

Indexed keywords

3 NITROTYROSINE; APOLIPOPROTEIN E; COLLAGEN TYPE 1; LANTHANUM CARBONATE; PHOSPHORUS; SEVELAMER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL CALCIFICATION; BONE REMODELING; BONE STRUCTURE; CALCIFICATION; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; MOUSE; NONHUMAN; OSSIFICATION; OXIDATIVE STRESS; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ANALYSIS OF VARIANCE; ANIMALS; AORTA; APOLIPOPROTEINS E; ATHEROSCLEROSIS; BLOOD CHEMICAL ANALYSIS; BONE DENSITY; COLLAGEN; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FEMALE; IMMUNOHISTOCHEMISTRY; LANTHANUM; MICE; MICE, INBRED STRAINS; POLYAMINES; RANDOM ALLOCATION; REFERENCE VALUES; RENAL INSUFFICIENCY, CHRONIC; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; UREMIA; VASCULAR CALCIFICATION;

EID: 84856947077     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfr254     Document Type: Article

References (38)

1. Drueke TB, Massy ZA. Atherosclerosis in CKD: differences from the general population. Nat Rev Nephrol 2010; 6: 723-735
2. Moe S, Drueke T, Cunningham J et al. Definition, evaluation, and classification of renal osteodystrophy: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006; 69: 1945-1953
3. Neves KR, Graciolli FG, dos Reis LM et al. Vascular calcification: contribution of parathyroid hormone in renal failure. Kidney Int 2007; 71: 1262-1270
4. Bucay N, Sarosi I, Dunstan CR et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998; 12: 1260-1268
5. Mathew S, Lund RJ, Strebeck F et al. Reversal of the adynamic bone disorder and decreased vascular calcification in chronic kidney disease by sevelamer carbonate therapy. J Am Soc Nephrol 2007; 18: 122-130
6. Naves M, Rodriguez-Garcia M, Diaz-Lopez JB et al. Progression of vascular calcifications is associated with greater bone loss and increased bone fractures. Osteoporos Int 2008; 19: 1161-1166
7. Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002; 62: 245-252
8. Nikolov IG, Joki N, Maizel J et al. Pleiotropic effects of the noncalcium phosphate binder sevelamer. Kidney Int Suppl 2006; 105: S16-S23
9. Hutchison AJ. Calcitriol, lanthanum carbonate, and other new phosphate binders in the management of renal osteodystrophy. Perit Dial Int 1999; 19 (Suppl 2): S408-S412
10. Massy ZA, Ivanovski O, Nguyen-Khoa T et al. Uremia accelerates both atherosclerosis and arterial calcification in apolipoprotein E knockout mice. J Am Soc Nephrol 2005; 16: 109-116
11. Phan O, Ivanovski O, Nguyen-Khoa T et al. Sevelamer prevents uremia-enhanced atherosclerosis progression in apolipoprotein E-deficient mice. Circulation 2005; 112: 2875-2882
12. Ivanovski O, Nikolov IG, Joki N et al. The calcimimetic R-568 retards uremia-enhanced vascular calcification and atherosclerosis in apolipoprotein E deficient (apoE-/-) mice. Atherosclerosis 2009; 205: 55-62
13. Phan O, Ivanovski O, Nikolov IG et al. Effect of oral calcium carbonate on aortic calcification in apolipoprotein E-deficient (apoE-/-) mice with chronic renal failure. Nephrol Dial Transplant 2008; 23: 82-90
14. Ivanovski O, Szumilak D, Nguyen-Khoa T et al. The antioxidant N-acetylcysteine prevents accelerated atherosclerosis in uremic apolipoprotein E knockout mice. Kidney Int 2005; 67: 2288-2294
15. Gazzerro E, Pereira RC, Jorgetti V et al. Skeletal overexpression of gremlin impairs bone formation and causes osteopenia. Endocrinology 2005; 146: 655-665
16. Chen NX, O'Neill KD, Duan D et al. Phosphorus and uremic serum up-regulate osteopontin expression in vascular smooth muscle cells. Kidney Int 2002; 62: 1724-1731
17. Steitz SA, Speer MY, Curinga G et al. Smooth muscle cell phenotypic transition associated with calcification: upregulation of Cbfa1 and downregulation of smooth muscle lineage markers. Circ Res 2001; 89: 1147-1154
18. Moe S, Zidehsarai M, Chambers M et al. Vegetarian compared to meat dietary protein source improves phosphorus homeostasis in CKD. Clin J Am Soc Nephrol 2011; 6: 257-264
19. Neven E, Dams G, Postnov A et al. Adequate phosphate binding with lanthanum carbonate attenuates arterial calcification in chronic renal failure rats. Nephrol Dial Transplant 2009; 24: 1790-1799
20. Halaszovich CR, Zitt C, Jungling E et al. Inhibition of TRP3 channels by lanthanides. Block from the cytosolic side of the plasma membrane. J Biol Chem 2000; 275: 37423-37428
21. Kyselovic J, Martinka P, Batova Z et al. Calcium channel blocker inhibits Western-type diet-evoked atherosclerosis development in ApoE-deficient mice. J Pharmacol Exp Ther 2005; 315: 320-328
22. Nakaya K, Harbidge DG, Wangemann P et al. Lack of pendrin HCO3-transport elevates vestibular endolymphatic [Ca21] by inhibition of acid-sensitive TRPV5 and TRPV6 channels. Am J Physiol Renal Physiol 2007; 292: F1314-F1321
23. Carrillo-Lopez N, Fernandez-Martin JL, Alvarez-Hernandez D et al. Lanthanum activates calcium-sensing receptor and enhances sensitivity to calcium. Nephrol Dial Transplant 2010; 25: 2930-2937
24. Spasovski GB, Sikole A, Gelev S et al. Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow-up. Nephrol Dial Transplant 2006; 21: 2217-2224
25. Moe SM, Chen NX. Mechanisms of vascular calcification in chronic kidney disease. J Am Soc Nephrol 2008; 19: 213-216
26. Zhou YB, Jin SJ, Cai Y et al. Lanthanum acetate inhibits vascular calcification induced by vitamin D3 plus nicotine in rats. Exp Biol Med (Maywood) 2009; 234: 908-917
27. Murshed M, Harmey D, Millan JL et al. Unique coexpression in osteoblasts of broadly expressed genes accounts for the spatial restriction of ECM mineralization to bone. Genes Dev 2005; 19: 1093-1104
28. Tonelli M, Pannu N, Manns B. Oral phosphate binders in patients with kidney failure. N Engl J Med 2010; 362: 1312-1324
29. Farhat GN, Cauley JA, Matthews KA et al. Volumetric BMD and vascular calcification in middle-aged women: the Study of Women's Health Across the Nation. J Bone Miner Res 2006; 21: 1839-1846
30. Hak AE, Pols HA, van Hemert AM et al. Progression of aortic calcification is associated with metacarpal bone loss during menopause: a population-based longitudinal study. Arterioscler Thromb Vasc Biol 2000; 20: 1926-1931
31. Rodriguez-Garcia M, Gomez-Alonso C, Naves-Diaz M et al. Vascular calcifications, vertebral fractures and mortality in haemodialysis patients. Nephrol Dial Transplant 2009; 24: 239-246
32. London GM, Marty C, Marchais SJ et al. Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol 2004; 15: 1943-1951
33. Nikolov IG, Joki N, Nguyen-Khoa T et al.: Chronic kidney disease bone and mineral disorder (CKD-MBD) in apolipoprotein E-deficient mice with chronic renal failure. Bone; 47: 156-163
34. D'Haese PC, Spasovski GB, Sikole A et al. A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int Suppl 2003; 85: S73-S78
35. Malluche HH, Siami GA, Swanepoel C et al. Improvements in renal osteodystrophy in patients treated with lanthanum carbonate for two years. Clin Nephrol 2008; 70: 284-295
36. Ferreira A, Frazao JM, Monier-Faugere MC et al. Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients. J Am Soc Nephrol 2008; 19: 405-412
37. Raggi P, James G, Burke SK et al. Decrease in thoracic vertebral bone attenuation with calcium-based phosphate binders in hemodialysis. J Bone Miner Res 2005; 20: 764-772
38. Sampath TK, Simic P, Moreno S et al. Sevelamer restores bone volume and improves bone microarchitecture and strength in aged ovariectomized rats. Endocrinology 2008; 149: 6092-6102